Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity (Q42985404)

12 November 2017

Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity (English)

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

26 October 2022

1 reference

1 reference

1 reference

1 reference

1 reference

M. Lenzi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677111

26 October 2022

P. J. Johnson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677111

26 October 2022

I. G. McFarlane

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677111

26 October 2022

G. Ballardini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677111

26 October 2022

H. M. Smith

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677111

26 October 2022

B. M. McFarlane

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677111

26 October 2022

C. Bridger

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677111

26 October 2022

D. Vergani

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677111

26 October 2022

F. B. Bianchi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677111

26 October 2022

R. Williams

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677111

26 October 2022

language of work or name

English

0 references

publication date

1 August 1991

1 reference

12 November 2017

3 August 1991

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1677111

full work available at URL

26 October 2022

https://api.elsevier.com/content/article/PII:014067369190418O?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

https://api.elsevier.com/content/article/PII:014067369190418O?httpAccept=text/plain

26 October 2022

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

26 October 2022

1 reference

12 November 2017

338

1 reference

12 November 2017

8762

1 reference

12 November 2017

277-280

1 reference

Hepatitis C virus antibodies among risk groups in Spain

12 November 2017

1

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Type 2 autoimmune hepatitis and hepatitis C virus infection

26 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

26 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis

26 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

26 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

26 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Hazards of interferon therapy for HBV-seronegative chronic hepatitis.

26 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein

26 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders

26 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

HCV testing in low-risk population

26 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

A radioimmunoassay for detection of circulating antibodies reacting with the hepatic asialoglycoprotein receptor protein

26 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis

26 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Autoimmune hepatitis in children and hepatitis C virus testing

26 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Enhanced antibody responses in active chronic hepatitis: relation to HLA-B8 and HLA-B12 and porto-systemic shunting

26 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Measles and rubella antibodies in patients with chronic liver disease

26 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process.

26 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

Intrafamilial transmission of hepatitis C virus

26 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)90418-O

26 October 2022

Identifiers

1 reference

12 November 2017

1 reference